Department of Hematology, Oncology and Clinical Immunology, Medical Faculty, University of Duesseldorf , Duesseldorf, Germany.
Institute of Human Genetics, Medical Faculty, University of Duesseldorf , Duesseldorf, Germany.
Expert Rev Anticancer Ther. 2020 Aug;20(8):703-714. doi: 10.1080/14737140.2020.1796644. Epub 2020 Aug 6.
Chronic myelomonocytic leukemia (CMML) is a hematological malignancy that is extremely variable regarding its clinical course. It may present either as a chronic disorder with mild symptoms and low disease burden for several years, thereby justifying a watch-and-wait-strategy, or may soon progress to acute myeloid leukemia (AML) leaving allogeneic stem cell transplantation as the only curative treatment option.
Attempts have been made to integrate clinical, cytogenetic, and molecular parameters into scoring systems aiming at providing reliable prognostic information. In this article, we discuss several prognostic parameters and validate prognostic scores in a cohort of 645 patients with CMML.
We show that the CPSS (CMML prognostic scoring system) is a useful prognostic tool. The integration of molecular data into the new CPSS-mol will further improve prognostic accuracy, primarily by identifying an increased proportion of higher-risk patients.
慢性髓单核细胞白血病（CMML）是一种血液系统恶性肿瘤，其临床表现极具异质性。CMML 患者的疾病进程可能数年都表现为慢性疾病，症状轻微，疾病负担低，因此可以采取观察等待策略；也可能很快进展为急性髓系白血病（AML），此时异基因造血干细胞移植是唯一的治愈性治疗选择。
目前已经尝试将临床、细胞遗传学和分子参数整合到评分系统中，旨在提供可靠的预后信息。本文讨论了几个预后参数，并在 645 例 CMML 患者的队列中验证了预后评分。
我们发现 CPSS（CMML 预后评分系统）是一种有用的预后工具。将分子数据纳入新的 CPSS-mol 中将会进一步提高预后准确性，主要是通过识别出更多的高风险患者。
